Impact of an online decision support tool for ductal carcinoma in situ (DCIS) using a pre-post design (AFT-25)

IF 6.1 1区 医学 Q1 ONCOLOGY
Elissa M. Ozanne, Kellyn Maves, Angela C. Tramontano, Thomas Lynch, Alastair Thompson, Ann Partridge, Elizabeth Frank, Deborah Collyar, Desiree Basila, Donna Pinto, Terry Hyslop, Marc D. Ryser, Shoshana Rosenberg, E. Shelley Hwang, Rinaa S. Punglia
{"title":"Impact of an online decision support tool for ductal carcinoma in situ (DCIS) using a pre-post design (AFT-25)","authors":"Elissa M. Ozanne, Kellyn Maves, Angela C. Tramontano, Thomas Lynch, Alastair Thompson, Ann Partridge, Elizabeth Frank, Deborah Collyar, Desiree Basila, Donna Pinto, Terry Hyslop, Marc D. Ryser, Shoshana Rosenberg, E. Shelley Hwang, Rinaa S. Punglia","doi":"10.1186/s13058-024-01891-w","DOIUrl":null,"url":null,"abstract":"The heterogeneous biology of ductal carcinoma in situ (DCIS), as well as the variable outcomes, in the setting of numerous treatment options have led to prognostic uncertainty. Consequently, making treatment decisions is challenging and necessitates involved communication between patient and provider about the risks and benefits. We developed and investigated an interactive decision support tool (DST) designed to improve communication of treatment options and related long-term risks for individuals diagnosed with DCIS. The DST was developed for use by individuals aged > 40 years with DCIS and is based on a disease simulation model that integrates empirical data and clinical characteristics to predict patient-specific impacts of six DCIS treatment choices. Personalized risk predictions for each treatment option were communicated using icon arrays and percentages for each outcome. Users of the DST were asked before and after interacting with the DST about: (1) awareness of DCIS treatment options, (2) willingness to consider these options, (3) knowledge of risks associated with DCIS, and (4) helpfulness of the DST. Data were collected from January 2019 to April 2022. Users’ median estimated risk of dying from DCIS in 10 years decreased from 9% pre-tool to 3% post-tool (p < 0.0001). 76% (n = 101/132) found the tool helpful. Information about DCIS treatment options and related risk predictions was effectively communicated, and a large majority participants found the DST to be helpful. Successfully informing patients about their treatment options and how their individual risks affect those options is a critical step in the decision-making process. Clinicaltrials.gov Identifier NCT02926911.","PeriodicalId":9222,"journal":{"name":"Breast Cancer Research","volume":null,"pages":null},"PeriodicalIF":6.1000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13058-024-01891-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The heterogeneous biology of ductal carcinoma in situ (DCIS), as well as the variable outcomes, in the setting of numerous treatment options have led to prognostic uncertainty. Consequently, making treatment decisions is challenging and necessitates involved communication between patient and provider about the risks and benefits. We developed and investigated an interactive decision support tool (DST) designed to improve communication of treatment options and related long-term risks for individuals diagnosed with DCIS. The DST was developed for use by individuals aged > 40 years with DCIS and is based on a disease simulation model that integrates empirical data and clinical characteristics to predict patient-specific impacts of six DCIS treatment choices. Personalized risk predictions for each treatment option were communicated using icon arrays and percentages for each outcome. Users of the DST were asked before and after interacting with the DST about: (1) awareness of DCIS treatment options, (2) willingness to consider these options, (3) knowledge of risks associated with DCIS, and (4) helpfulness of the DST. Data were collected from January 2019 to April 2022. Users’ median estimated risk of dying from DCIS in 10 years decreased from 9% pre-tool to 3% post-tool (p < 0.0001). 76% (n = 101/132) found the tool helpful. Information about DCIS treatment options and related risk predictions was effectively communicated, and a large majority participants found the DST to be helpful. Successfully informing patients about their treatment options and how their individual risks affect those options is a critical step in the decision-making process. Clinicaltrials.gov Identifier NCT02926911.
采用前后设计的在线决策支持工具对乳腺导管原位癌(DCIS)的影响 (AFT-25)
乳腺导管原位癌(DCIS)的生物学特性各不相同,治疗效果也不尽相同,治疗方案众多,导致预后不确定。因此,做出治疗决定具有挑战性,需要患者和医生就风险和益处进行沟通。我们开发并研究了一种交互式决策支持工具(DST),旨在改善确诊为 DCIS 患者的治疗方案及相关长期风险的沟通。DST 是专为年龄大于 40 岁的 DCIS 患者开发的,它基于一个疾病模拟模型,该模型综合了经验数据和临床特征,可预测六种 DCIS 治疗选择对患者的具体影响。每种治疗方案的个性化风险预测都使用图标阵列和每种结果的百分比来传达。DST 用户在与 DST 互动之前和之后被问及:(1) 对 DCIS 治疗方案的认识,(2) 考虑这些方案的意愿,(3) 对 DCIS 相关风险的了解,以及 (4) DST 的帮助。数据收集时间为 2019 年 1 月至 2022 年 4 月。用户估计 10 年内死于 DCIS 的风险中位数从工具使用前的 9% 降至工具使用后的 3%(p < 0.0001)。76%的用户(n = 101/132)认为该工具很有帮助。关于 DCIS 治疗方案和相关风险预测的信息得到了有效传达,绝大多数参与者认为 DST 有帮助。成功地让患者了解他们的治疗方案及其个体风险对这些方案的影响是决策过程中的关键一步。Clinicaltrials.gov Identifier NCT02926911。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Breast Cancer Research
Breast Cancer Research 医学-肿瘤学
自引率
0.00%
发文量
76
期刊介绍: Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信